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Abstract
Objective: The aim of this study was to assess the antibody response to combined passive-active immu-
nization versus active immunization against hepatitis B in 71 patients with acute leukemia with nega-
tive hepatitis B virus serology at presentation. 
Materials and Methods: The first group (n=28) received a double dose of hepatitis B vaccine at 0, 1, 
2 and 6 months and immunoglobin (HBIG) at 0 and 1 month concurrently with vaccine but at a dif-
ferent intramuscular site. The second group (n=43) received double dose of hepatitis B vaccine at 0, 
1, 2, and 6 months. HBsAg and anti-HBs titers were determined one month after the 1st, 2nd, 3rd and 
4th doses of vaccine. 
Results: In the vaccine-only group, 2.56%, 8.33%, 14.28% and 34.29% of patients developed anti-HBs 
titer ≥10 IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, respectively. In the HBIG group, 91.30%, 
91.30%, 69.56% and 73.91% of patients developed anti-HBs titer ≥10 IU/L after the 1st, 2nd, 3rd and 
4th doses of vaccine, respectively. Those in the vaccine-HBIG group maintained their anti-HBs titer 
≥10 IU/L from the 1st to the 4th doses. In the vaccine-only group, 34.29% of patients gained protective 
antibody titer after receiving the 4th dose of vaccine. Subgroup analysis of age (pediatric vs adult) and 
disease (acute lymphoblastic leukemia vs acute myeloid leukemia) groups showed no effect of either 
on the development of protective antibody titer. The incidence of HBsAg positivity one month after 
the 4th dose of vaccine was 8.62%. No patient became positive for anti-HCV or HIV antibody before 
or after chemo therapy.
Conclusion: Combined HBIG and vaccine may protect acute leukemia patients during the intensive 
chemotherapy period. (Turk J Hematol 2010; 27: 156-61)
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Özet
Amaç: Bu çalışmada, prezantasyonda negatif Hepatit B virüsü serolojisine sahip akut lösemili 71 has-
tada Hepatit B virüsüne karşı aktif aşılama karşısında birleşik pasif aktif aşılamaya yönelik antikor 
yanıtının değerlendirilmesi amaçlanmıştır. Introduction
Hepatitis B is one of the most important causes 
of acute and chronic hepatitis. Children with malig-
nant disease are at an especially high risk for devel-
oping hepatitis B virus (HBV) infection from immu-
nosuppression secondary to chemotherapy, radio-
therapy and multiple blood transfusions. Most of the 
children infected with HBV develop chronic hepati-
tis. This plays an adverse prognostic role in terms of 
their disease-free survival because of delays in che-
motherapy. The increasing potential for the cure of 
childhood malignant diseases emphasizes the need 
for a method of reducing hepatitis and its sequelae 
in these children.
Hepatitis B virus infection is prevalent in India. 
Among blood donors, pregnant women and the 
general population whose carrier frequency is 
2%-4% and hepatitis B surfact antibody (anti-HBs) 
positivity is around 18%-20% [1]. A high proportions 
of children treated for malignant disorders demon-
strate seroconversion for HBV infection markers [2].
The high prevalence of HBV infection and rela-
tive failure of active immunization in patients with 
leukemia on therapy have prompted a search for 
alternative forms of prophylaxis [3]. Various studies 
have observed a decreased rate of transmission of 
the infection with passive immunization [4]. Thus, 
for protection against HBV infection, both active and 
passive immunization have been tried [5,6]. 
Since there are very few studies in this context, 
this study was undertaken to determine the efficacy 
of immunization (both active and passive) against 
HBV infection in acute leukemia patients.
Materials and Methods
The aims and objectives of this study were to 
determine the incidence of hepatitis B surface anti-
gen (HBsAg) positivity before treatment, the efficacy 
of hepatitis B vaccine along with HBIG (hepatitis B 
immunoglobulin) in patients with acute leukemia, 
the anti-HBs titer level in the course of treatment 
and up to six months, and the HBsAg positivity rate 
in the course of treatment up to six months. A total 
of 114 patients with acute leukemia were tested for 
HBsAg and anti-HBs titer before starting treatment. 
Of the 114 patients, 3 were positive for HBsAg and 
111 patients were negative for HBsAg. Out of 111 
patients, 40 had anti-HBs titer ≥10 IU/L and 71 
patients had anti-HBs titer <10 IU/L. Thus, 71 
patients were included in this study. This project 
was approved by the All India Institute of Medical 
Sciences (AIIMS) Ethics Committee. It is a prospec-
tive comparative trial including patients with acute 
leukemia with HBsAg, anti-HBs negativity before 
treatment and with anti-HBs titer <10 IU/L. Those 
patients already immunized and with protective 
anti-HBs titer ≥10 IU/L were excluded from the 
study. Those who already completed immunization 
against hepatitis B and with anti-HBs titer <10 IU/L 
were also included in this study. Immunization was 
started from induction. The first group (n=28) 
received hepatitis B vaccine (Engerix B - 
GlaxoSmithKline Biologicals, double dose, i.e. ≤11 
years 20 mcg and >11 years 40 mcg) at 0, 1, 2, and 
6 months and HBIG (Hepabig- VHB Life Sciences 
Limited, Mumbai, India at a dose of 40 IU/kg maxi-
mum of 800 IU) at 0 and 1 month concurrently with 
Yöntem ve Gereçler: Birinci grup (n=28), 0. ay, 1. ay, 2. ay ve 6. ay zaman noktalarında ikili hepatit 
B aşısı dozu ve 0. ay, 1. ay zaman noktalarında aşı ile eşzamanlı olarak (ancak kas içi olarak) immu-
noglobin (HBIG) almıştır. İkinci grup (n=43), 0. ay, 1. ay, 2. ay ve 6. ay zaman noktalarında ikili 
hepatit B aşısı dozu almıştır. HBsAg ve anti HBs titreleri, aşının 1. dozu, 2. dozu, 3. dozu ve 4. dozun-
dan sonra yapılmıştır. 
Bulgular: Yalnızca aşı yapılan grupta hastaların %2.56, %8.33, %14.28 ve %34.29’unda, sırasıyla 1., 
2., 3. ve 4. aşı dozu verildikten sonra anti HBs titresi ≥10 IU/l oluşmuştur. HBIG grubunda, hastaların 
%91.30, %91.30, %69.56 ve %73.91’inde, sırasıyla 1., 2., 3. ve 4. aşı dozu verildikten sonra anti HBs 
titresi ≥10 IU/l oluşmuştur. HBIG alan hastalar, 1. dozdan 4. doza kadar ≥10 IU/l HBs titre değerini 
muhafaza etmiştir. Yalnızca aşı verilen grupta, hastaların %34.29’u 4. aşı dozu verildikten sonra 
koruyucu antikor titresi edinmiştir. Yaş (yetişkin karşısında pediatrik) ve hastalık (akut myeloid lösemi 
karşısında akut lenfoblastik lösemi) gruplarında, koruyucu antikor titresi gelişimi bakımında herhangi 
bir etki gözlenmemiştir. Aşının 4. dozundan bir ay sonar HBsAg pozitivite insidansı %8.62’dir. 
Kemoterapiden önce sonra, hiçbir hastada anti HCV ve HIV antikoru için pozitivite gelişmemiştir.
Sonuç: Kombine HBIG ve aşı, yoğun kemoterapi periyodu sırasında akut lösemi hastalarını koruyabilir. 
(Turk J Hematol 2010; 27: 156-61)
Anahtar kelimeler: Akut lösemi, Hepatit B aşısı, Hepatit B immunoglobin
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second group (n=43) received only hepatitis B vac-
cine (Engerix B - double dose, i.e. ≤11 years 20 mcg 
and >11 years 40 mcg) at 0, 1, 2, and 6 months. 
HBsAg and anti-HBs titer were determined one 
month after the 1st, 2nd, 3rd and 4th doses of vac-
cine. In those patients who were given Engerix B 
and HBIG and became HBsAg positive after starting 
treatment, subsequent doses of Engerix B and HBIG 
were not given. Anti-hepatitis C virus (HCV) total 
and human immunodeficiency virus (HIV) antibody 
were also tested before starting treatment and one 
month after the 4th dose of vaccine. HbsAg was 
tested using Hepanostika® HBsAg Ultra (bioMerieux 
bv Boseind 15, 5281RM Boxtel, The Netherlands). 
Anti-HBs was tested using VIDAS® (bioMérieux® 
sa, France). 
Fisher’s exact test and chi-square test were used 
to compare proportions between the groups. 
McNemar test was used to compare proportions 
within the group. Wilcoxon rank-sum (Mann-
Whitney U) test was used to compare the medians. 
Two-sample t test was used to compare the median 
between the groups in equal variances. The statisti-
cal tests were performed by using STATA 9.0 and 
SPSS software version 11.5 for Windows®. 
Results
Of these 114 patients, 3 (3%) were positive for 
HBsAg and 111 patients (97%) were negative for 
HBsAg. Out of 111 patients, 40 (36%) had anti-HBs 
titer ≥10 IU/L and 71 (64%) had anti-HBs titer <10 
IU/L. Of those patients with anti-HBs titer ≥10 IU/L, 
7 (18%) patients had past history of jaundice, 13 
(33%) had history of previous vaccination and 20 
(49%) had no history of jaundice or previous vacci-
nation. A significant statistical difference (p=0.04) 
was found between pediatric and adult patients in 
anti-HBs titer ≥10 IU/L and anti- HBs titer <10 IU/L 
groups. The majority of pediatric patients had anti-
HBs titer ≥10 IU/L compared to adults before start-
ing chemotherapy. 
The median age was 22 years (range, 1-52); 49 
(69.01%) were male and 22 (30.99%) were female 
(Table 1). The total number of pediatric (≤18 yrs) 
patients was 31 (43.66%) and of adult (>18 yrs) 
patients was 40 (56.34%). The total number of acute 
lymphoblastic leukemia (ALL) patients was 38 
(53.52%) and of acute myeloid leukemia (AML) 
patients was 33 (46.48%). Nine patients (12.67%) 
died due to their disease and chemotherapy com-
plications before the 2nd dose of vaccine; thus, 62 
patients received a 2nd vaccine dose. Three patients 
died before receiving their 3rd dose of vaccine; thus, 
59 patients received a 3rd vaccine dose. One patient 
died before receiving their 4th dose of vaccine; thus, 
58 patients received a 4th vaccine dose.
In the vaccine-only group, 2.56%, 8.33%, 14.28% 
and 34.29% patients developed anti- HBs titer ≥10 
IU/L after the 1st, 2nd, 3rd and 4th doses of vaccine, 
respectively. In the HBIG-vaccine group, 91.30%, 
91.30%, 69.56% and 73.91% patients developed anti-
HBs titer ≥10 IU/L after the 1st, 2nd, 3rd and 4th doses 
of vaccine, respectively, and 8.69%, 8.69%, 30.43% 
and 26.09% patients had anti-HBs titer <10 IU/L 
after the 1st, 2nd, 3rd and 4th doses of vaccine, 
respectively. Significantly statistical differences 
(Table 2) in anti-HBs titer (≥10 U/L) were seen 
between the two vaccine groups after the 1st, 2nd, 
3rd and 4th doses of vaccine. Those who received 
HBIG maintained their anti-HBs titer ≥10 IU/L even 
one month after the 4th dose of vaccine. In the vac-
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Table 1. Baseline patient characteristics according to vaccine group
Parameters HBIG-Vaccine  Vaccine-only  P  value
 n=28    n=43  (Mann-Whitney
 Median  Median  test)
 (range)  (range)
Age in years  18 (3-44)  25 (1-52)  0.20
DDTT days  10 (2-142)  14 (1-147)  0.42
BT units  2 (0-18)  3 (0-40)  0.87
S. Bilirubin mg/dl  0.8 (0.6-5.8)  0.8 (0.5-4.6)  1.00
AST U/dl  27 (12-451)  29 (10-127)  0.96
ALT U/dl  31.5 (10-169)  36 (11-295)  0.87
ALP U/dl  243 (129-552)  232 (96-1270)  0.71
S. Protein g/dl  6.35 (4-7.6)  6.8 (4-9.5)  0.02*
S. Albumin g/dl   3.55 (2.1-4.6)  3.9 (2.3-4.8)  0.02*
S. Globulin g/dl  2.75 (1.9-4.3)  2.9 (1.7-5.1)  0.21*
Sex M/F  22 (44.9)/  27 (55.10)/  0.12 #
  6 (39.44)  16 (72.73) 
ALL/AML  20 (52.63)/  18 (47.37)/  0.01#
  8 (24.24)  25 (75.76) 
Age ≤18 yrs/  20 (71.42)/  11 (25.58)/  0.0002#
>18 yrs  8 (28.58)  32 (74.42) 
HBIG: Hepatitis B immunoglobin; DDTT: Duration of diagnosis to received treatment; 
BT: Blood transfusion; AST: Aspartate aminotransferase; ALT: Alanine aminotransfer-
ase; ALP: Alkaline phosphatase 
*done by two sample t test; #done by Fisher’s exact testcine-only group, after the 4th dose, anti-HBs titer 
≥10 IU/L was achieved in 34.29% of patients, which 
was a very small proportion compared to the HBIG 
group. In both groups, a subgroup analysis was 
done between the ALL vs AML groups and pediatric 
vs adult groups. No significant differences were 
found between the ALL vs AML groups or between 
the pediatric vs adult groups. 
In the pediatric age group, 72.72%, 58.33%, 
47.61% and 41.37% patients developed anti-HBs titer 
≥10 IU/L after the 1st, 2nd, 3rd and 4th doses of vac-
cine, respectively, whereas in the adult age group, 
27.28%, 41.67%, 52.38% and 58.63% patients devel-
oped anti-HBs titer ≥10 IU/L after the 1st, 2nd, 3rd and 
4th doses of vaccine, respectively. This showed that 
pediatric patients lost their anti-HBs titer gradually 
from the 1st to the 4th dose of vaccine. On the other 
hand, an increasing number of adult patients gained 
anti-HBs titer ≥10 IU/L gradually from the 1st to the 
4th dose of vaccine. Statistical differences in anti-
HBs titer ≥10 IU/L were seen between the two age 
groups after the 1st (p=0.002) and 2nd (p=0.01) 
dose of vaccine, but not after the 3rd (p=0.40) and 
4th (p=1.00) dose of vaccine. Thus, more pediatric 
patients developed anti-HBs titer ≥10 IU/L after the 
1st and 2nd doses of vaccine compared to adult 
patients. Though more adult patients gained protec-
tive anti-HBs titer gradually from the 3rd to 4th doses 
of vaccine, when compared to the pediatric age 
group, the difference was statistically insignificant.
In the ALL group, 81.81%, 70.84%, 47.62% and 
55.17% patients developed anti-HBs titer ≥10 IU/L 
after the 1st, 2nd, 3rd and 4th doses of vaccine, 
respectively, whereas in the AML group, 18.19%, 
29.16%, 52.38% and 44.83% patients developed anti-
HBs titer ≥10 IU/L after the 1st dose, 2nd, 3rd and 4th 
doses of vaccine, respectively. After the 1st dose of 
vaccine, a statistical difference in anti-HBs titer ≥10 
IU/L was seen between the ALL and AML groups. 
No statistically significant differences were found 
after administration of the other doses (p values: 
0.06 after 2nd dose, 0.28 after 3rd dose and 1.00 after 
4th dose). A significant number of ALL patients 
developed protective antibody titer after the 1st vac-
cine dose compared to AML patients; thereafter, 
both groups behaved similarly. 
One month after the 4th dose of vaccine, out of 58 
patients, 5 patients (8.6%) were found HBsAg-
positive. Among the HBsAg-positive patients, 1 
(4.34%) was in the HBIG group and the remaining 4 
(11.42%) were in the vaccine-only group. Of the 
HBsAg-positive patients, 3 had ALL and 2 had AML. 
No significant difference (p=0.63) in HBsAg positiv-
ity was found between the vaccine groups. After 210 
days of follow up, none of the patients was found to 
be positive for anti-HCV or HIV antibody. 
Discussion 
A study from India showed that 47.8% of ALL 
patients were positive for HBsAg after therapy. In 
order to reduce the impact of HBV infection, sched-
ules for active immunization, double doses of active 
immunization and both active and passive immuni-
zation against this infection have been investigated. 
The HBsAg positivity rate (3%) in our study is 
quite similar to that of other studies performed in 
the general population in India. But the anti-HBs 
positivity rate in our study is quite high (40%) com-
pared to other studies (18-20%) performed from 
India. This is probably due to the increased aware-
ness of hepatitis B vaccination in the general popu-
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Table 2. Anti-HBs titer according to vaccine group at the different 
time points
Parameters <10  IU/L,  ≥10 IU/L  P value
     (Fisher’s 
     exact  test)
One month after 1st dose 
HBIG-Vaccine  2 (8.69)  21 (91.30) 
n=23, no (%)      0.0001
Vaccine-only  38 (97.43)  1 (2.56)
n=39, no (%)   
One month after 2nd dose 
HBIG-Vaccine  2 (8.69)  21 (91.30)
n=23, no (%)      0.0001
Vaccine-only  33 (91.66)  3 (8.33)
n=36, no (%)   
One month after 3rd dose   
HBIG-Vaccine 7(30.43)  16  (69.56) 
n=23, no (%)      0.0001
Vaccine-only  30 (85.71)  5 (14.28)
n=35, no (%)   
One month after 4th dose 
HBIG-Vaccine  6 (26.09)  17 (73.91) 
n=23, no (%)      0.003
Vaccine-only  23 (65.71)  12 (34.29) 
n=35, no (%)   
HBIG: Hepatitis B immunoglobinlation. The HBsAg positivity rate of acute leukemia 
in this study was slightly high (3%) compared to that 
of an older study (1.85%) in ALL done by Marwaha 
et al. [2] from Chandigarh, India. It is probably due 
to the less sensitive method used for detection of 
HBsAg in 2001. Anti-HBs titer ≥10 IU/L was seen in 
more pediatric patients compared to adults, due to 
the increased awareness of hepatitis B vaccination 
in the pediatric population.
Goyal et al. [3] showed that after administration 
of double-dose vaccine during induction, consolida-
tion and maintenance (0-1-2-12 months) chemo-
therapy, 19.7% patients developed anti-HBs titers and 
anti-HBs titer ≥10 IU/L was achieved in only 10.5% of 
patients. They detected HBsAg in 48.79% of their 
patients during the course of treatment. Another 
study from India by Somjee et al. [7] showed that at 
the end of six doses of vaccine (0-1-2-3-4-12), 29.75% 
of patients developed anti-HBs titers, and of them, 
only 18.9% had anti-HBs titer ≥10 IU/L. In the course 
of treatment, 43% of patients developed HBsAg posi-
tivity. A similar dose schedule as in our study (0-1-2-6) 
was tried in adult patients with acute leukemia (ALL 
& AML) by Gurina et al. [8]. In 30 patients, the rate of 
antibody positivity was 50% after the 4th dose of vac-
cine and 6.7% became infected with HBV over the 
three-year follow-up. A more intensive vaccination 
schedule (0-1-2-6-12) was used by Yetgin et al. [9] in 
82 patients with childhood ALL. They found that the 
rate of antibody positivity was 35.4% after the 5th 
dose of vaccine, and 4.8% became infected with 
HBV after the end of vaccination. Our results are 
quite similar with the Yetgin et al. trial. An exact 
comparison with other studies is not possible 
because different vaccination schedules were used. 
In our study, more patients (34.29%) developed pro-
tective antibody titer after receiving their 4th dose of 
vaccine compared with other trials done by Goyal et 
al. [3] and Somjee et al. [7]. This is possibly due to 
the more severe immunosuppressive chemothera-
py schedule used in their study. In our study, after a 
seven-month follow-up period, a small number 
(11.42%) of patients developed HBsAg positivity 
compared with other trials done by Goyal et al. and 
Somjee et al. This is due to improved infection con-
trol measures, safer blood supply in our hospital 
and the short duration of follow-up in our study. In 
spite of active immunization with recombinant DNA 
vaccine, some patients became infected with HBV 
infection. Thus, active immunization with recombi-
nant DNA vaccine has a minimal role in these 
immunosuppressed patients while they are on 
aggressive therapy.
A total of 28 patients received both vaccine and 
HBIG. Passively transferred immunity generated 
high titers of antibodies in these patients in the first 
3 months. However, once these were eliminated 
over a period of another 3 months, active immuni-
zation was unable to confer sustained protection at 
7 months. Therefore, it should be stressed that pas-
sive prophylaxis alone needs to be administered 
during the entire course of aggressive chemothera-
py. Kavakli et al. [4] studied 22 patients with leuke-
mia who received HBIG (800 IU once per month for 
3 doses), together with vaccine at a different intra-
muscular site. HBV infection was not observed in 
any of the patients at the 4th and 12th months of 
serological follow-up. At the end of the first year, the 
antibody response reached 85%. In another study by 
Meral et al. [6], passive immunization with immu-
noglobulin (monthly for four doses) was given at 
the time of aggressive chemotherapy, and subse-
quently these patients were actively immunized 
with vaccine (40 mcg, 1-2-12 months) from the third 
month of maintenance therapy. Their rate of anti-
HBs positivity was 90.3% at the end of the four 
doses, and at the end of the three-year follow-up, 
only 5 patients (16%) lost the protective antibody 
titers. In another Indian study by Somjee et al. [5], 
five doses of hepatitis B vaccine (ENGERIX-
SmithKline Beecham) along with HBIG (HEPABIG-
VHB Pharmaceuticals) were given in 31 ALL patients. 
Their rates of anti-HBs positivity were 89.6% at the 
end of 6 months, and at the end of 9 months, only 8 
(42%) patients had lost the protective antibody titer. 
The rate of HBV infection was 27% at the end of 9 
months. In our study, 73.91% of patients had devel-
oped anti-HBs titer ≥10 IU/L 1 month after the 4th 
dose of vaccine. This is a slightly inferior response 
compared to results of the Kavakli et al. [4], Meral et 
al. [6] and Somjee et al. [7] trials. The inferior 
response is possibly due to lesser doses of HBIG 
used in our trial (i.e. 2 doses of HBIG in our trial, 3 
doses in Kavakli et al. trial, 4 doses in Meral et al. 
trial and 5 doses in Somjee et al. trial). Thus, a com-
parison of our study and other studies clearly shows 
that more doses of HBIG are required to achieve the 
maximum protective anti-HBs titers. Apart from 
that, HBIG may protect patients during the intensive 
chemotherapy period, but there must be sufficient 
antibody level during the entire period to decrease 
the rate of HBV infection in these patients. HBIG 
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maximum immunosuppression exists in addition to 
increased chances of exposure. This could be used 
in combination with more doses of active immuni-
zation, which may result in higher rates of antibody 
response.
In normal individuals, the rate of seroconversion 
following hepatitis B vaccine is almost 96%, and pro-
tective antibody levels can be achieved in 93% [3]. 
In the present study, despite the use of a double 
dose of vaccine and a more intensified vaccination 
program, seroconversion could be achieved in only 
34.29% and 73.91% of the patients in the vaccine-
only and vaccine-HBIG groups, respectively. This is 
because immunosuppression in leukemic patients 
resulting from the disease as well as the use of ste-
roids lead to diminished response to initial or boost-
er vaccination. Therefore, passive immunization 
with hyperimmunoglobulin followed by active 
immunization starting during maintenance therapy 
or after cessation of intensive chemotherapy may 
be a better alternative to achieve permanent protec-
tive antibody titers.
In the HBIG group, subgroup analysis was done 
between the ALL vs AML and pediatric vs adult 
groups. No statistically significant differences were 
found between the ALL vs AML groups or between 
the pediatric vs adult groups. Thus, differences in 
age and disease were not responsible for develop-
ment of protective antibody titer. HBsAg positivity 
rate was similar between the two vaccine groups in 
the short follow-up period (7 months). The out-
come of long-term follow-up might be different in 
terms of HBsAg positivity. Thus, long- term follow-
up will be required to determine the efficacy of vac-
cination and the HBsAg positivity rate.
In conclusion, HBIG may protect patients during 
the intensive chemotherapy period, but there must 
be sufficient antibody level during the entire period 
to decrease the rate of HBV infection in these 
patients. To increase the level of protective antibody 
titers (≥10 IU/L), both active and passive immuniza-
tion are required. A large prospective multicenter 
randomized controlled trial is needed to address 
this issue. 
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